Compagnie Lombard Odier SCmA Acquires 23,382 Shares of Pfizer Inc. $PFE

Key Points

• Compagnie Lombard Odier SCmA increased its stake in Pfizer Inc. by 6.3%, acquiring an additional 23,382 shares, bringing its total holdings to 392,418 shares valued at approximately $9.5 million.
• Pfizer's recent quarterly earnings report showed earnings per share of $0.78, exceeding analyst expectations, with revenues of $14.65 billion, up 10.3% year-over-year.
• The stock's current consensus rating is "Hold," with a price target averaging around $28.12, reflecting mixed opinions from analysts following recent upgrades and downgrades.

Compagnie Lombard Odier SCmA lifted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 392,418 shares of the biopharmaceutical company's stock after acquiring an additional 23,382 shares during the quarter. Compagnie Lombard Odier SCmA's holdings in Pfizer were worth $9,512,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after buying an additional 4,629,976 shares during the period. Northern Trust Corp raised its position in shares of Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock worth $1,579,340,000 after acquiring an additional 3,943,397 shares in the last quarter. Amundi lifted its stake in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Invesco Ltd. boosted its position in shares of Pfizer by 2.8% during the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock valued at $767,709,000 after purchasing an additional 838,198 shares in the last quarter. Finally, Deutsche Bank AG grew its stake in Pfizer by 7.0% in the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock worth $715,581,000 after purchasing an additional 1,846,436 shares during the period. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on PFE. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday. Morgan Stanley upped their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Berenberg Bank lowered their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Finally, Bank of America boosted their price target on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Up 0.1%

Shares of NYSE PFE opened at $24.05 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The firm's 50-day moving average price is $24.61 and its 200-day moving average price is $24.18. The stock has a market capitalization of $136.74 billion, a price-to-earnings ratio of 12.79, a P/E/G ratio of 0.78 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. Pfizer's payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.